By Dennis Ford, Founder & CEO, LSN
After the huge success of RESI Boston, which attracted over 700 attendees for an unprecedented number of face to face meetings, it’s time to look ahead to this winter’s conference season. RESI will be joining the JPM fray for our largest event yet. The 11th Redefining Early Stage Investments (RESI) Conference will take place on January 10th in San Francisco.
2016 has seen a grand RESI tour, beginning with a sellout event in San Francisco, then to Houston, and up to Toronto for our first international RESI event, and home to Boston in the fall. For 2017 we’ll once again open the year with a splash in San Francisco. With other events focusing on late stage or publicly traded companies, RESI San Francisco will offer early stage companies and investors an opportunity to get the most out of the wild week when the biotech and medtech world gathers by the Bay. As RESI SF is highly likely to hit capacity again, we encourage you to register early.
RESI is a venue for entrepreneurs to meet with 10 categories of investors that LSN tracks including Family Offices, Corporate Venture Funds, Angel Groups, Venture Philanthropy, Venture Capital and more. Through the RESI Partnering, fundraising executives can have up to 16 scheduled meetings as well as many more ad-hoc meetings with diverse life science investors who fit their company’s technology sector, indication and stage of development. Additionally, through an expansive series of panels and workshops, attendees will have the chance to hear firsthand accounts from investors explaining their current investment mandates and process for identifying and qualifying candidates.